Halozyme Therapeutics | HALO - Operating Expenses


Halozyme Therapeutics reported $136.34M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 129.75M 9.76M Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amarin USD 51.37M 14.6M Sep/2025
Amgen USD 5.9B 773M Dec/2025
Baxter International USD 2.63B 95.8M Sep/2025
Cytokinetics USD 168.69M 9.58M Sep/2025
DBV Technologies USD 37.05M 4.06M Sep/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Halozyme Therapeutics USD 136.34M 13.06M Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
MannKind USD 63.35M 2.51M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
United Therapeutics USD 6.59B 6.07B Sep/2025